Ovary Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OVR059 MIFTS: 49	Ovary Adenocarcinoma Categories: Cancer diseases, Endocrine diseases, Rare diseases, Reproductive diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Ovary Adenocarcinoma

MalaCards integrated aliases for Ovary Adenocarcinoma:

Name: Ovary Adenocarcinoma ¹² ¹⁵

Ovarian Adenocarcinoma ¹² ⁵⁸ ⁶ ¹⁷ ⁷⁰

Adenocarcinoma of the Ovary ¹²

Adenocarcinoma of Ovary ⁵⁸

Ovarian Adenoacanthoma ¹²

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Reproductive diseases Endocrine diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of female genital organs

Malignant neoplasm of ovary

Orphanet: ⁵⁸

Rare gynaecological and obstetric diseases

External Ids:

Disease Ontology ¹² DOID:3713

NCIt ⁵⁰ C7700

ICD10 via Orphanet ³³ C56

UMLS via Orphanet ⁷¹ C0948216

Orphanet ⁵⁸ ORPHA213504

EFO ¹⁷ EFO_0006460

UMLS ⁷⁰ C0948216

Sources

Summaries for Ovary Adenocarcinoma

Disease Ontology : ¹² An ovarian carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Ovary Adenocarcinoma, also known as ovarian adenocarcinoma, is related to endometrioid ovary carcinoma and clear cell adenocarcinoma. An important gene associated with Ovary Adenocarcinoma is INHBA (Inhibin Subunit Beta A), and among its related pathways/superpathways are TGF-Beta Pathway and Toll-like Receptor Signaling Pathway. The drugs Paclitaxel and Nintedanib have been mentioned in the context of this disorder. Affiliated tissues include ovary, lymph node and t cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Sources

Related Diseases for Ovary Adenocarcinoma

Diseases related to Ovary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 469)

#	Related Disease	Score	Top Affiliating Genes
1	endometrioid ovary carcinoma	32.2	TP53 PIK3CA KRAS CTNNB1 ARID1A
2	clear cell adenocarcinoma	31.7	TP53 PIK3CA ARID1A
3	mucinous adenocarcinoma	31.6	TP53 KRAS ERBB2 CEACAM5
4	appendix adenocarcinoma	31.5	KRAS HRAS
5	ovarian clear cell adenocarcinoma	31.3	TP53 PIK3CA ARID1A
6	ovarian cystadenocarcinoma	31.2	TP53 SERPINA3 PIK3CA MIR744 MIR30A MIR17
7	papillary adenocarcinoma	31.2	TP53 MIR30A ERBB2 CEACAM5 BRCA1
8	adenofibroma	31.1	TP53 BRAF ARID1A
9	clear cell adenofibroma	31.0	PIK3CA ARID1A
10	serous cystadenocarcinoma	31.0	TP53 PIK3CA MIR30A KRAS HRAS ESS2
11	small cell carcinoma	30.9	TP53 KRAS ERBB2
12	papillary serous adenocarcinoma	30.8	TP53 MIR30A KRAS HRAS CEACAM5 BRCA1
13	pseudomyxoma peritonei	30.8	TP53 KRAS CTNNB1 CEACAM5
14	cystadenocarcinoma	30.7	TP53 SERPINA3 PIK3CA MIR30A HRAS ERBB2
15	adenoma	30.6	TP53 PIK3CA KRAS CTNNB1 BRAF
16	cystadenoma	30.6	SERPINA3 CEACAM5 BRCA1
17	teratoma	30.6	TP53 KRAS CTNNB1 CEACAM5
18	ovarian clear cell carcinoma	30.5	TP53 PIK3CA KRAS ARID1A
19	ovarian serous carcinoma	30.5	TP53 KRAS BRCA1
20	fallopian tube carcinoma	30.5	TP53 ERBB2 BRCA1
21	endometrial hyperplasia	30.5	TP53 KRAS CTNNB1 ARID1A
22	endocervical adenocarcinoma	30.5	TP53 PIK3CA ERBB2 CEACAM5
23	pilocytic astrocytoma	30.5	TP53 PIK3CA KRAS HRAS BRAF
24	rectum cancer	30.5	MIR17 KRAS HRAS CEACAM5
25	myoma	30.4	TP53 KRAS CEACAM5
26	adenosarcoma	30.4	TP53 SERPINA3 ERBB2
27	wolffian duct adenocarcinoma	30.4	KRAS HRAS
28	malignant astrocytoma	30.4	TP53 SERPINA3 MIR17 H2AC18 ERBB2 CTNNB1
29	squamous cell carcinoma	30.3	TP53 PIK3CA HRAS ERBB2 CTNNB1 CEACAM5
30	endometrial adenocarcinoma	30.3	TP53 KRAS ERBB2 CTNNB1
31	cervical squamous cell carcinoma	30.3	TP53 PIK3CA KRAS CTNNB1
32	colorectal adenocarcinoma	30.3	TP53 KRAS HRAS ERBB2 CTNNB1 CEACAM5
33	sarcoma	30.2	TP53 PIK3CA KRAS HRAS CTNNB1 BRAF
34	carcinosarcoma	30.2	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
35	ovarian disease	30.1	TP53 MIR30A MIR17 ERBB2 CTNNB1 BRCA1
36	cervical cancer	30.1	TP53 PIK3CA MIR17 HRAS ERBB2 CTNNB1
37	adenocarcinoma	30.1	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
38	peripheral nervous system disease	30.1	TP53 SERPINA3 MIR17 HRAS H2AC18 ERBB2
39	ovarian serous cystadenocarcinoma	30.1	TP53 SERPINA3 PIK3CA MIR744 MIR30A MIR17
40	endometrial cancer	30.1	TP53 SERPINA3 PIK3CA KRAS HRAS ERBB2
41	rhabdomyosarcoma	30.0	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
42	thyroid gland cancer	29.9	TP53 PIK3CA MIR17 KRAS HRAS ERBB2
43	esophageal cancer	29.9	TP53 PIK3CA MIR30A KRAS HRAS ERBB2
44	myeloma, multiple	29.9	TP53 PIK3CA MIR30A MIR17 KRAS HRAS
45	ovarian cancer	29.8	TP53 PIK3CA OVAAL MIR30A MIR17 KRAS
46	lynch syndrome	29.8	TP53 PIK3CA MIR17 KRAS HRAS H2AC18
47	skin melanoma	29.8	TP53 SERPINA3 PIK3CA KRAS HRAS H2AC18
48	hepatocellular carcinoma	29.7	TP53 PIK3CA MIR30A MIR17 KRAS HRAS
49	lung cancer susceptibility 3	29.6	TP53 PIK3CA MIR30A MIR17 KRAS HRAS
50	leukemia, acute myeloid	29.6	TP53 SERPINA3 PIK3CA MIR744 MIR30A MIR17

Graphical network of the top 20 diseases related to Ovary Adenocarcinoma:

Sources

Symptoms & Phenotypes for Ovary Adenocarcinoma

GenomeRNAi Phenotypes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

²⁶ (show top 50) (show all 76)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-11	10.46	KRAS
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-116	10.46	BRCA1 PIK3CA
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-117	10.46	KRAS
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-130	10.46	C1RL
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-135	10.46	BRCA1
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-145	10.46	KRAS
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-157	10.46	PIK3CA
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-16	10.46	PIK3CA
9	Decreased shRNA abundance (Z-score < -2)	GR00366-A-165	10.46	KRAS
10	Decreased shRNA abundance (Z-score < -2)	GR00366-A-166	10.46	PIK3CA
11	Decreased shRNA abundance (Z-score < -2)	GR00366-A-168	10.46	KRAS
12	Decreased shRNA abundance (Z-score < -2)	GR00366-A-177	10.46	C1RL KRAS PIK3CA
13	Decreased shRNA abundance (Z-score < -2)	GR00366-A-185	10.46	BRCA1
14	Decreased shRNA abundance (Z-score < -2)	GR00366-A-190	10.46	PIK3CA
15	Decreased shRNA abundance (Z-score < -2)	GR00366-A-193	10.46	KRAS
16	Decreased shRNA abundance (Z-score < -2)	GR00366-A-196	10.46	KRAS
17	Decreased shRNA abundance (Z-score < -2)	GR00366-A-216	10.46	KRAS PIK3CA
18	Decreased shRNA abundance (Z-score < -2)	GR00366-A-23	10.46	KRAS
19	Decreased shRNA abundance (Z-score < -2)	GR00366-A-27	10.46	KRAS
20	Decreased shRNA abundance (Z-score < -2)	GR00366-A-33	10.46	KRAS
21	Decreased shRNA abundance (Z-score < -2)	GR00366-A-42	10.46	PIK3CA
22	Decreased shRNA abundance (Z-score < -2)	GR00366-A-43	10.46	BRCA1
23	Decreased shRNA abundance (Z-score < -2)	GR00366-A-49	10.46	C1RL KRAS PIK3CA
24	Decreased shRNA abundance (Z-score < -2)	GR00366-A-50	10.46	BRCA1 KRAS
25	Decreased shRNA abundance (Z-score < -2)	GR00366-A-53	10.46	BRCA1 KRAS PIK3CA
26	Decreased shRNA abundance (Z-score < -2)	GR00366-A-57	10.46	C1RL
27	Decreased shRNA abundance (Z-score < -2)	GR00366-A-66	10.46	KRAS
28	Decreased shRNA abundance (Z-score < -2)	GR00366-A-7	10.46	BRCA1
29	Decreased shRNA abundance (Z-score < -2)	GR00366-A-71	10.46	BRCA1
30	Decreased shRNA abundance (Z-score < -2)	GR00366-A-73	10.46	C1RL
31	Decreased shRNA abundance (Z-score < -2)	GR00366-A-93	10.46	KRAS
32	Decreased viability	GR00055-A-1	10.05	BRAF HRAS KRAS PIK3CA
33	Decreased viability	GR00055-A-2	10.05	BRAF HRAS KRAS PIK3CA
34	Decreased viability	GR00055-A-3	10.05	KRAS
35	Decreased viability	GR00106-A-0	10.05	KRAS
36	Decreased viability	GR00221-A-1	10.05	HRAS KRAS PIK3CA
37	Decreased viability	GR00221-A-2	10.05	HRAS KRAS PIK3CA
38	Decreased viability	GR00221-A-3	10.05	HRAS
39	Decreased viability	GR00221-A-4	10.05	BRAF PIK3CA
40	Decreased viability	GR00249-S	10.05	BRAF
41	Decreased viability	GR00301-A	10.05	BRAF KRAS
42	Decreased viability	GR00381-A-1	10.05	BRAF KRAS
43	Decreased viability	GR00402-S-2	10.05	PIK3CA
44	Increased shRNA abundance (Z-score > 2)	GR00366-A-120	9.94	KRAS
45	Increased shRNA abundance (Z-score > 2)	GR00366-A-132	9.94	C1RL
46	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.94	C1RL
47	Increased shRNA abundance (Z-score > 2)	GR00366-A-137	9.94	BRCA1
48	Increased shRNA abundance (Z-score > 2)	GR00366-A-139	9.94	BRCA1
49	Increased shRNA abundance (Z-score > 2)	GR00366-A-149	9.94	BRAF
50	Increased shRNA abundance (Z-score > 2)	GR00366-A-161	9.94	ERBB2

MGI Mouse Phenotypes related to Ovary Adenocarcinoma:

⁴⁶ (show all 14)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.24	ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
2	integument	MP:0010771	10.18	BRAF BRCA1 CTNNB1 ERBB2 HRAS INHBA
3	muscle	MP:0005369	10.17	ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
4	embryo	MP:0005380	10.16	ARID1A BRAF BRCA1 CTNNB1 ERBB2 INHBA
5	craniofacial	MP:0005382	10.14	ARID1A BRAF CTNNB1 ERBB2 HRAS INHBA
6	digestive/alimentary	MP:0005381	10.13	BRAF BRCA1 CTNNB1 ERBB2 HRAS INHBA
7	neoplasm	MP:0002006	10.1	ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
8	limbs/digits/tail	MP:0005371	10.06	BAX BRAF BRCA1 C1RL CTNNB1 ERBB2
9	normal	MP:0002873	9.97	ARID1A BRAF BRCA1 CTNNB1 ERBB2 HRAS
10	no phenotypic analysis	MP:0003012	9.91	ARID1A CTNNB1 ESS2 HRAS KRAS PIK3CA
11	renal/urinary system	MP:0005367	9.86	BAX BRAF BRCA1 CTNNB1 HRAS INHBA
12	reproductive system	MP:0005389	9.85	ARID1A BAX BRAF BRCA1 CTNNB1 ERBB2
13	respiratory system	MP:0005388	9.56	BAX BRAF BRCA1 CTNNB1 ERBB2 HRAS
14	skeleton	MP:0005390	9.4	ARID1A BAX BRAF BRCA1 C1RL CTNNB1

Sources

Drugs & Therapeutics for Ovary Adenocarcinoma

Drugs for Ovary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Synonyms:

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester

12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

157069-30-2

33069-62-4

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine

7 Epi taxol

7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.

7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.

7-epi-Paclitaxel

7-Epipaclitaxel

7-Epi-paclitaxel

7-epi-Taxol

7-Epitaxol

7-Epi-taxol

AB00513812

ABI 007

abi-007

ABI007

ABI-007

Abraxane

Abraxane (TN)

Abraxane I.V. Suspension

Abraxis BioScience brand of albumin-bound paclitaxel

AC1L1IOG

AC1L1VJI

AC1L9AVF

AC-675

ACon1_002231

albumin-bound paclitaxel

Ambotz33069-62-4

ANX-513

Anzatax

Asotax

BIDD:PXR0046

Bio-0076

Bio1_000362

Bio1_000851

Bio1_001340

Bio2_000416

Bio2_000896

BMS 181339-01

BMS-181339

BMS-181339-01

BPBio1_000320

BRD-A23723433-001-01-2

BRD-A28746609-001-04-0

BRD-K62008436-001-03-1

Bris taxol

Bristaxol

BSPBio_000290

BSPBio_001152

BSPBio_002614

C07394

C466458

C47H51NO14

Capxol

CCRIS 8143

CHEBI:103439

CHEBI:45863

CHEMBL100910

CHEMBL418410

CHEMBL48

CID36314

CID441276

CID4666

CID6713921

CID6915727

cMAP_000068

CPD-8718

D00491

DB01229

DHP-107

DHP-208

DivK1c_000441

DRG-0190

DTS-301

Ebetaxel

EmPAC

Epitaxol

EU-0101201

Genaxol

Genetaxyl

Genexol

Genexol-PM

HMS1362J13

HMS1568O12

HMS1792J13

HMS1922K08

HMS1990J13

HMS2090D07

HMS2093K15

HMS501G03

HSDB 6839

I06-0014

IDI1_000441

IDI1_002171

Intaxel

KBio1_000441

KBio2_000492

KBio2_002016

KBio2_002509

KBio2_003060

KBio2_004584

KBio2_005077

KBio2_005628

KBio2_007152

KBio2_007645

KBio3_000903

KBio3_000904

KBio3_001834

KBio3_002987

KBioGR_000492

KBioGR_001893

KBioGR_002509

KBioSS_000492

KBioSS_002016

KBioSS_002517

LipoPac

LMPR0104390001

Lopac0_001201

LS-31070

MBT 0206

MEGxp0_001940

Micellar Paclitaxel

Mitotax

MLS000863266

MLS001077297

MLS002154218

MLS002172439

MLS002695976

MolPort-001-742-627

MolPort-003-665-783

MolPort-003-932-365

MPI-5018

nab-paclitaxel

Nanotaxel

NCGC00024995-02

NCGC00024995-03

NCGC00024995-04

NCGC00024995-05

NCGC00024995-06

NCGC00024995-07

NCGC00164367-01

NCGC00164367-02

NCGC00164367-03

nchembio.188-comp1

nchembio.2007.34-comp9

nchembio.215-comp9

nchembio853-comp6

NCI60_000601

Neuro_000060

NINDS_000441

NK 105

Nova-12005

NP-010981

NSC 125973

NSC125973

NSC-125973

NSC358882

OAS-PAC-100

OncoGel

Onxal

Onxol

Onxol, Taxol, Nov-Onxol, Paclitaxel

P1632

Paclical

Pacligel

paclitaxel

Paclitaxel

Paclitaxel (JAN/USP)

Paclitaxel (JAN/USP/INN)

Paclitaxel (Taxol)

Paclitaxel [USAN:INN:BAN]

Paclitaxel, (4 alpha)-isomer

Paxceed

Paxene

Paxoral

Plaxicel

Praxel

Prestwick0_000155

Prestwick1_000155

Prestwick2_000155

Prestwick3_000155

Probes2_000350

QW 8184

S1150_Selleck

S-8184 Paclitaxel Injectable Emulsion

SDCCGMLS-0066823.P001

SDP-013

SMP1_000228

SMR000394086

SMR000857385

SPBio_000943

SPBio_002229

Spectrum_001536

SPECTRUM1503908

Spectrum2_000872

Spectrum3_001057

Spectrum4_001197

Spectrum5_001491

ST50306996

T 7402

T1912_SIGMA

T7191_SIGMA

T7402_SIGMA

TA1

TaxAlbin

Taxol

TAXOL

TAXOL (TN)

Taxol a

Taxol A

Taxol Konzentrat

TAXOL, 10-EPI,

Taxol, bris

Taxol.RTM. (Registered Trademark)

TXL

UNII-P88XT4IS4D

UPCMLD-DP108:001

UPCMLD-DP108:002

Vascular Wrap

weekly paclitaxel

Xorane

Yewtaxan

Nintedanib

Approved

Phase 2

656247-17-5

56843413

Carboplatin

Approved

Phase 2

41575-94-4

10339178 498142 38904

Synonyms:

(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum

/h1-3H2,(H,7,8)(H,9,10)

1,1-Cyclobutanedicarboxylate diammine platinum (II)

1,1-Cyclobutanedicarboxylate diammine platinum(II)

2*-1

2*1H2

41575-94-4

70903-55-8

AC-1457

AC1L8I6U

Ambap41575-94-4

azanide

Blastocarb

BSPBio_003145

C 2538

C2043

C2538_SIGMA

C6H10N2O4Pt

Carbopaltin

Carboplat

carboplatin

Carboplatin

Carboplatin (JAN/USP/INN)

Carboplatin (USAN)

Carboplatin [USAN:INN:BAN:JAN]

Carboplatine

Carboplatine [French]

Carboplatino

Carboplatino [Spanish]

Carboplatinum

Carboplatinum [Latin]

Carbosin

Carbotec

Cbdca

CBDCA

CCRIS 3404

CHEBI:31355

CHEMBL1351

CHEMBL288376

CID10339178

CID2567

CID38904

CID426756

CID498142

CID5352133

CID6398587

CID6603770

cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum

cis-(1,1-cyclobutanedicarboxylato)diammineplatinum(II)

cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)

cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato) platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum

cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)

cis-Diammine(cyclobutanedicarboxylato)platinum II

Cyclobutane-1,1-dicarboxylate

cyclobutane-1,1-dicarboxylic acid

D01363

DB00958

Diammine(1,1-cyclobutanedicarboxylato)platinum (II)

Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum

diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum

Diammine-1,1-cyclobutane dicarboxylate platinum II

DivK1c_000892

EINECS 255-446-0

Ercar

EU-0100230

HMS1921J16

HMS2090M05

HMS2092B22

HMS502M14

HSDB 6957

I14-2390

IDI1_000892

InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6

IUPAC: Azane

JM 8

JM8

JM-8

KBio1_000892

KBio2_002009

KBio2_004577

KBio2_007145

KBio3_002645

KBioGR_000713

KBioSS_002009

Lopac0_000230

Lopac-C-2538

LS-117689

MolPort-003-665-501

MolPort-003-845-609

NCGC00015223-01

NCGC00093695-01

NCGC00094961-01

NCGC00094961-02

NCGC00094961-03

NCGC00162099-01

NCGC00162099-02

NCGC00167800-01

NCGC00178242-01

nchembio.573-comp10

nchembio773-comp2

nchembio873-comp3

Nealorin

Neocarbo

NINDS_000892

NSC 201345

NSC 241240

NSC201345

NSC241240

NSC-241240

Paraplatin

Paraplatin (TN)

Paraplatin, Carboplatin

Paraplatin-AQ

Platinum(+2) Cation

platinum(2+)

Platinum(II), (1, 1-cyclobutanedicar

Platinum, {diammine[1,1-cyclobut

Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)

Ribocarbo

S1215_Selleck

SPBio_000716

Spectrum_001529

SPECTRUM1502106

Spectrum2_000898

Spectrum3_001503

Spectrum4_000337

Spectrum5_001094

UNII-BG3F62OND5

Sargramostim

Approved, Investigational

Phase 2

123774-72-1, 83869-56-1

Synonyms:

123774-72-1

D05803

Leukine

Leukine (TN)

Recombinant human granulocyte-macrophage colony stimulating factor

rGM-CSF

rHu GM-CSF

Sargramostim

Sargramostim (genetical recombination)

Sargramostim (genetical recombination) (JAN)

Sargramostim (USAN/INN)

Aldesleukin

Approved

Phase 2

85898-30-2, 110942-02-4

Molgramostim

Investigational

Phase 2

99283-10-0

Albumin-Bound Paclitaxel

Phase 2

Vaccines

Phase 2

Adjuvants, Immunologic

Phase 2

Freund's Adjuvant

Phase 2

Immunologic Factors

Phase 2

Anti-Retroviral Agents

Phase 2

Anti-Infective Agents

Phase 2

Antiviral Agents

Phase 2

Anti-HIV Agents

Phase 2

Cisplatin

Approved

Phase 1

15663-27-1

84093 441203 2767

Synonyms:

(SP-4-1)-diamminedichloridoplatinum

(SP-4-1)-diamminedichloroplatinum

(SP-4-2)-diamminedichloridoplatinum

(SP-4-2)-diamminedichloroplatinum

Abiplatin

Biocisplatinum

Briplatin

CACP

Carboquone

CDDP

CHEBI:35852

CID441203

Cis Pt II

cis-[PtCl2(NH3)2]

cis-DDP

Cis-DDP

Cis-Diaminedichloroplatinum

cis-diamminedichloridoplatinum(II)

cis-Diamminedichloroplatinum

Cis-Diamminedichloroplatinum

cis-diamminedichloroplatinum(II)

cis-Dichlorodiammineplatinum(II)

Cismaplat

Cisplatin

Cisplatine

cisplatino

Cisplatino

Cisplatinum

Cisplatyl

Citoplationo

CPD0-1392

CPDC

CPDD

DB00515

DDP

DDPT

Diamminedichloroplatinum

EU-0100918

Lederplatin

nchembio773-comp1

Neoplatin

Peyrone's chloride

Peyrone's salt

Plastin

Platamine

Platiblastin

Platidiam

Platinex

Platinol

Platinol-AQ

Platinoxan

Platinum Ammine Chloride

Platinum Ammonium Chloride

Platinum Diamine Dichloride

Randa

trans-DDP

Trans-DDP

Trans-Diaminedichloroplatinum

trans-diamminedichloridoplatinum(II)

Trans-Diamminedichloroplatinum

Trans-Dichlorodiammine Platinum

Trans-Platinumdiammine Dichloride

Bevacizumab

Approved, Investigational

Phase 1

216974-75-3

Synonyms:

216974-75-3

antiVEGF

Anti-VEGF Humanized Monoclonal Antibody

anti-VEGF monoclonal antibody

Anti-VEGF monoclonal antibody

Avastin

Avastin (TN)

bevacizumab

Bevacizumab

Bevacizumab (genetical recombination)

Bevacizumab (genetical recombination) (JAN)

bevacizumab-awwb

D06409

R-435

rhuMAb-VEGF

Cyclophosphamide

Approved, Investigational

Phase 1

50-18-0, 6055-19-2

2907

Synonyms:

(-)-Cyclophosphamide

(+-)-Cyclophosphamide

(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

(RS)-Cyclophosphamide

1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine

1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin

2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide

4-Hydroxy-cyclophosphan-mamophosphatide

50-18-0

60007-95-6

6055-19-2 (monohydrate)

75526-90-8

AC1L1EQQ

AI3-26198

Anhydrous cyclophosphamide

Anhydrous, cyclophosphamide

ASTA

Asta B 518

ASTA B518

B 518

B-518

bis(2-Chloroethyl)phosphami de cyclic propanolamide

bis(2-Chloroethyl)phosphamide cyclic propanolamide ester

Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester

BRN 0011744

BSPBio_002099

C 0768

C07888

C7H15Cl2N2O2P

CB 4564

CB-4564

CCRIS 188

CHEBI:4027

CHEMBL32520

CHEMBL88

Ciclofosfamida

Ciclofosfamida [INN-Spanish]

Ciclofosfamide

Ciclophosphamide

Ciclophosphamide [INN]

CID2907

Clafen

Claphene

CPA

CTX

Cycloblastin

Cyclophosphamid

cyclophosphamide

Cyclophosphamide

Cyclophosphamide (anhydrous form)

Cyclophosphamide (anhydrous)

Cyclophosphamide (INN)

Cyclophosphamide (TN)

Cyclophosphamide anhydrous

Cyclophosphamide monohydrate

Cyclophosphamide Monohydrate

Cyclophosphamide Sterile

Cyclophosphamide, (+-)-Isomer

Cyclophosphamide, (R)-isomer

Cyclophosphamide, (S)-isomer

Cyclophosphamides

Cyclophosphamidum

Cyclophosphamidum [INN-Latin]

Cyclophosphan

Cyclophosphane

Cyclophosphanum

Cyclophosphoramide

Cyclostin

Cyklofosfamid

Cyklofosfamid [Czech]

Cytophosphan

Cytophosphane

Cytoxan

Cytoxan (TN)

Cytoxan Lyoph

D,L-Cyclophosphamide

D07760

DB00531

DivK1c_000246

EINECS 200-015-4

Endoxan

Endoxan R

Endoxana

Endoxanal

Endoxan-Asta

Endoxane

Enduxan

EU-0100238

Genoxal

Hexadrin

HMS2090A12

HSDB 3047

IDI1_000246

KBio1_000246

KBio2_001338

KBio2_003906

KBio2_006474

KBio3_001319

KBioGR_000888

KBioSS_001338

Lopac0_000238

Lopac-C-0768

LS-1302

LS-99787

Lyophilized Cytoxan

Mitoxan

MolPort-001-783-420

Monohydrate, cyclophosphamide

N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide

N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide

NCGC00015209-01

NCGC00015209-03

NCGC00015209-06

NCGC00091741-02

NCGC00091741-03

NCI60_002097

NCI-C04900

Neosar

NINDS_000246

NSC 26271

NSC26271

NSC-26271

NSC273033

NSC273034

Occupation, cyclophosphamide exposure

Procytox

RCRA waste no. U058

Rcra waste number U058

Rcra Waste Number U058

Revimmune

S1217_Selleck

Semdoxan

Sendoxan

Senduxan

SK 20501

SPBio_001071

Spectrum_000858

Spectrum2_001146

Spectrum3_000370

Spectrum4_000304

Spectrum5_000795

STK177249

STOCK2S-91217

UNII-6UXW23996M

WLN: T6MPOTJ BO BN2G2G

Zyklophosphamid

Zyklophosphamid [German]

Angiogenesis Inhibitors

Phase 1

Antineoplastic Agents, Immunological

Phase 1

Antirheumatic Agents

Phase 1

Immunosuppressive Agents

Phase 1

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	OVax®: A Feasibility Study Using a DNP-Modified Autologous Ovarian Tumor Cell Vaccine as Therapy in Ovarian Cancer Patients After Relapse:	Unknown status	NCT00660101	Phase 1, Phase 2
2	Randomized Double Blind Placebo-controlled Phase II Trial of Vargatef® (Nintedanib) in Addition to First Line Chemotherapy With Interval Debulking Surgery in Patients With Adenocarcinoma of the Ovary, the Fallopian Tube or Serous Adenocarcinoma of the Peritoneum	Completed	NCT01583322	Phase 2	vargatef;placebo
3	Vaccine Therapy With Tumor Specific p53 Peptides in Adult Patients With Low Burden Adenocarcinoma of the Ovary	Terminated	NCT00001827	Phase 2
4	A Phase 1/2, Open Label, Multi-center Study of VAL-083 in Patients With Recurrent Platinum Resistant Ovarian Cancer	Withdrawn	NCT03281681	Phase 1, Phase 2	VAL-083, Dianhydrogalactitol
5	Phase I Study of Cisplatin Hyperthermic Intraperitoneal Chemotherapy Dose Escalation After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma Previously Treated by Chemotherapy and Completed by Bevacizumab for 15 Months	Completed	NCT02217956	Phase 1	Cisplatin;Bevacizumab
6	A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy	Active, not recruiting	NCT03608618	Phase 1	Cyclophosphamide
7	The CINSARC Genomic Signature as a Predictor of Resectability of High Grade Serous Ovarian Adenocarcinomas	Recruiting	NCT04248231

Search NIH Clinical Center for Ovary Adenocarcinoma

Sources

Genetic Tests for Ovary Adenocarcinoma

Sources

Anatomical Context for Ovary Adenocarcinoma

MalaCards organs/tissues related to Ovary Adenocarcinoma:

⁴⁰

Ovary, Lymph Node, T Cells, Thyroid, Endothelial, Colon, Cervix

Sources

Publications for Ovary Adenocarcinoma

Articles related to Ovary Adenocarcinoma:

(show top 50) (show all 1060)

#	Title	Authors	PMID	Year
1	Prediction of cancer driver mutations in protein kinases. ⁶	Torkamani A...Schork NJ	18339846	2008
2	Folic acid functionalized gold nanoclusters for enabling targeted fluorescence imaging of human ovarian cancer cells. ⁶¹	Hada AM...Astilean S	33592715	2021
3	Influence of core extension and side chain nature in targeting G-quadruplex structures with perylene monoimide derivatives. ⁶¹	Busto N...Garcia B	33550073	2021
4	Ovarian adenocarcinoma with metastases in a white rhinoceros. ⁶¹	Kim SH...Sur JH	33427119	2021
5	Long-Term Treatment Results for Ovarian Tumors with Malignant Effusion in Seven Dogs. ⁶¹	Itoh T...Shii H	33770181	2021
6	Cashew apple (Anacardium occidentale L.) extract from a by-product of juice processing: assessment of its toxicity, antiproliferative and antimicrobial activities. ⁶¹	Sousa JMS...Dionisio AP	33568870	2021
7	Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. ⁶¹	Shorstova T...Witcher M	33087508	2021
8	Features of the Copy Number Variation of Certain Genes in Tumor Cells in Patients with Serous Ovarian Adenocarcinoma. ⁶¹	Kutilin DS...Porkhanova NV	33452985	2021
9	Prognostic gene profiles in the tumor microenvironment of ovarian serous adenocarcinoma. ⁶¹	Tian R...Guo S	33049689	2021
10	Comparative Analysis of Cell-Cell Contact Abundance in Ovarian Carcinoma Cells Cultured in Two- and Three-Dimensional In Vitro Models. ⁶¹	Kutova OM...Balalaeva IV	33291824	2020
11	Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas. ⁶¹	Bandala-Jacques A...Herrera LA	33052898	2020
12	Identification and validation of core genes for serous ovarian adenocarcinoma via bioinformatics analysis. ⁶¹	Zhu R...Zhang Q	32934713	2020
13	Ovarian Carcinoma Uncloaked by Hydatidosis: An Intraoperative Epiphany. ⁶¹	Almas T...Khan MK	33274151	2020
14	Targeted Detection of Cyclooxygenase-1 in Ovarian Cancer. ⁶¹	Malerba P...Uddin MJ	33062161	2020
15	Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy. ⁶¹	Gaweda W...Bilewicz A	33092037	2020
16	Genetic and epigenetic profiling of BRCA1/2 in ovarian tumors reveals additive diagnostic yield and evidence of a genomic BRCA1/2 DNA methylation signature. ⁶¹	Aref-Eshghi E...Sadikovic B	32483276	2020
17	A Series of Isatin-Hydrazones with Cytotoxic Activity and CDK2 Kinase Inhibitory Activity: A Potential Type II ATP Competitive Inhibitor. ⁶¹	Al-Salem HS...Rahman AFMM	32992673	2020
18	An Antibody-Drug Conjugate Targeting MUC1-Associated Carbohydrate CA6 Shows Promising Antitumor Activities. ⁶¹	Nicolazzi C...Blanc V	32451330	2020
19	Breast and Axillary Lymph Node Metastasis from Ovarian Cancer: A Case Report. ⁶¹	Longo R...Rozzi A	32750046	2020
20	Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. ⁶¹	Yu KH...Kohane IS	32807164	2020
21	Investigation into antiproliferative activity and apoptosis mechanism of new arene Ru(ii) carbazole-based hydrazone complexes. ⁶¹	Sathiya Kamatchi T...Malecki JG	32776042	2020
22	Gone but Not Forgotten: Ovarian Metastasis From a Colon Carcinoma in a 19-Year-Old Female. ⁶¹	Almas T...Khan MK	32874796	2020
23	Robotic Tumor Debulking off External Iliac Vessels for the Management of Recurrent Ovarian Cancer. ⁶¹	Mutlu L...Menderes G	31610315	2020
24	Antioxidant, antiproliferative and healing properties of araticum (Annona crassiflora Mart.) peel and seed. ⁶¹	Prado LG...Pastore GM	32466931	2020
25	A Tertiary Cancer Center Experience of 52 Cases of Primary Ovarian Mucinous Adenocarcinomas. ⁶¹	Das G...Natarajan M	33354551	2020
26	Bevacizumab-induced dysphonia: A case report with brief review of literature. ⁶¹	Lam SY...Cheng K	31771464	2020
27	Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines. ⁶¹	Varankar SS...Bapat SA	31241128	2020
28	Identification of Human Ovarian Adenocarcinoma Cells with Cisplatin-resistance by Feature Extraction of Gray Level Co-occurrence Matrix Using Optical Images. ⁶¹	Huang CL...Chiu WT	32527052	2020
29	Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. ⁶¹	Chhikara BS...Parang K	32370213	2020
30	Prognostic Significance of the MAD1L1 1673 G: A Polymorphism in Ovarian Adenocarcinomas. ⁶¹	Bandala-Jacques A...Herrera LA	32488223	2020
31	Characterization of ascites-derived aldehyde dehydrogenase-positive ovarian cancer stem cells isolated from Leghorn chickens. ⁶¹	Tiwari A...Ramachandran R	32241506	2020
32	MCL1 regulates cell death, tumor growth and chemosensitivity to sabutoclax in ovarian adenocarcinoma. ⁶¹	Li C...Li P	31754782	2020
33	Identification of Radiation-Dose-Dependent Expressive Genes in Individuals Exposed to External Ionizing Radiation. ⁶¹	Yamaguchi M...Kashiwakura I	31910119	2020
34	Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base. ⁶¹	Nasioudis D...Ko EM	31839340	2020
35	Stomach gastrin is regulated by sodium via PPAR-α and dopamine D1 receptor. ⁶¹	Xu P...Felder RA	31794424	2020
36	Comparative study of the antitumoral activity of phosphine-thiosemicarbazone gold(I) complexes obtained by different methodologies. ⁶¹	Gonzalez-Barcia LM...Pedrido R	31786438	2020
37	The Relationship of FOXR2 Gene Expression Profile with Epithelial-Mesenchymal Transition Related Markers in Epithelial Ovarian Cancer. ⁶¹	Asadollahi S...Farzaneh	32683876	2020
38	CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. ⁶¹	Porcellini S...Traversari C	32117253	2020
39	Analysis of Clinicopathological Features of Cervical Mucinous Adenocarcinoma with a Solitary Ovarian Metastatic Mass as the First Manifestation. ⁶¹	Liu S...Zheng S	33061592	2020
40	Extended Pelvic Resections as Part of Secondary Cytoreduction for Relapsed Ovarian Adenocarcinoma. ⁶¹	Bacalbasa N...Brezean I	31882505	2020
41	Ovarian adenocarcinoma metastasis mimicking psoas abscess on imaging: a case report. ⁶¹	Kharbach Y...Khallouk A	33708322	2020
42	Triggered ferroptotic polymer micelles for reversing multidrug resistance to chemotherapy. ⁶¹	Gao M...Zhao Y	31520887	2019
43	Double-Emulsion Copolyester Microcapsules for Sustained Intraperitoneal Release of Carboplatin. ⁶¹	Cymbaluk-Ploska A...El Fray M	31817672	2019
44	A Severe, Refractory Case of Mucous Membrane Pemphigoid After Treatment With Pembrolizumab: Brief Communication. ⁶¹	Bezinelli LM...Buzaid AC	31246641	2019
45	GSVD- and tensor GSVD-uncovered patterns of DNA copy-number alterations predict adenocarcinomas survival in general and in response to platinum. ⁶¹	Bradley MW...Alter O	31463421	2019
46	Hyperthermia potentiates cisplatin cytotoxicity and negative effects on mitochondrial functions in OVCAR-3 cells. ⁶¹	Sukovas A...Paskauskas S	31332716	2019
47	Interaction with Blood Proteins of a Ruthenium(II) Nitrofuryl Semicarbazone Complex: Effect on the Antitumoral Activity. ⁶¹	Demoro B...Tomaz AI	31394747	2019
48	Fabrication of gold-silver core-shell nanoparticles for performing as ultrabright SERS-nanotags inside human ovarian cancer cells. ⁶¹	Hada AM...Astilean S	30974419	2019
49	Suppression of autophagy enhances preferential toxicity of epothilone A and epothilone B in ovarian cancer cells. ⁶¹	Rogalska A...Marczak A	31029905	2019
50	Photodynamic Therapy of Ovarian Carcinoma Cells with Curcumin-Loaded Biodegradable Polymeric Nanoparticles. ⁶¹	Duse L...Bakowsky U	31208085	2019

Sources

Genes for Ovary Adenocarcinoma

Genes related to Ovary Adenocarcinoma (1 elite genes):

(show all 44)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	INHBA	Inhibin Subunit Beta A	Protein Coding	353.75	Causative germline mutation ⁵⁸ DISEASES inferred ¹⁵	24302632
2	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	31.57	Likely pathogenic ⁶ DISEASES inferred ¹⁵	18339846
3	TP53	Tumor Protein P53	Protein Coding	15.29	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
4	CTNNB1	Catenin Beta 1	Protein Coding	13.78	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
5	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	13.24	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
6	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	10.91	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
7	BAX	BCL2 Associated X, Apoptosis Regulator	Protein Coding	9.97	DISEASES inferred ¹⁵ GeneCards inferred via : Expressions (show sections)
8	SERPINA3	Serpin Family A Member 3	Protein Coding	8.43	DISEASES inferred ¹⁵ ¹⁵
9	MIR17	MicroRNA 17	RNA Gene	7.92	DISEASES inferred ¹⁵ ¹⁵
10	H2AC18	H2A Clustered Histone 18	Protein Coding	7.87	DISEASES inferred ¹⁵ ¹⁵
11	MIR30A	MicroRNA 30a	RNA Gene	7.73	DISEASES inferred ¹⁵ ¹⁵
12	CEACAM5	CEA Cell Adhesion Molecule 5	Protein Coding	7.02	DISEASES inferred ¹⁵
13	MIR744	MicroRNA 744	RNA Gene	7	DISEASES inferred ¹⁵ ¹⁵
14	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	6.97	DISEASES inferred ¹⁵
15	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	6.95	DISEASES inferred ¹⁵
16	ESS2	Ess-2 Splicing Factor Homolog	Protein Coding	6.93	DISEASES inferred ¹⁵
17	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	6.91	DISEASES inferred ¹⁵
18	C1RL	Complement C1r Subcomponent Like	Protein Coding	6.86	GeneCards inferred via : Expressions (show sections)
19	OVAAL	Ovarian Adenocarcinoma Amplified Long Non-Coding RNA	RNA Gene	6.8	DISEASES inferred ¹⁵
20	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	6.76	DISEASES inferred ¹⁵
21	KRT7	Keratin 7	Protein Coding	6.72	DISEASES inferred ¹⁵
22	MIR135A1	MicroRNA 135a-1	RNA Gene	6.69	DISEASES inferred ¹⁵ ¹⁵
23	MIR1307	MicroRNA 1307	RNA Gene	6.68	DISEASES inferred ¹⁵ ¹⁵
24	PTEN	Phosphatase And Tensin Homolog	Protein Coding	6.56	DISEASES inferred ¹⁵
25	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	6.47	DISEASES inferred ¹⁵
26	CFHR2	Complement Factor H Related 2	Protein Coding	6.43	DISEASES inferred ¹⁵ ¹⁵
27	GNAS	GNAS Complex Locus	Protein Coding	6.4	DISEASES inferred ¹⁵
28	MUC16	Mucin 16, Cell Surface Associated	Protein Coding	6.3	DISEASES inferred ¹⁵
29	EGFR	Epidermal Growth Factor Receptor	Protein Coding	6.29	DISEASES inferred ¹⁵
30	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	6.26	DISEASES inferred ¹⁵
31	PAX8	Paired Box 8	Protein Coding	6.23	DISEASES inferred ¹⁵
32	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	6.23	DISEASES inferred ¹⁵
33	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	6.18	DISEASES inferred ¹⁵
34	WT1	WT1 Transcription Factor	Protein Coding	6.14	DISEASES inferred ¹⁵
35	ESR1	Estrogen Receptor 1	Protein Coding	6.14	DISEASES inferred ¹⁵
36	CDH1	Cadherin 1	Protein Coding	6.1	DISEASES inferred ¹⁵
37	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.09	DISEASES inferred ¹⁵
38	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	6.09	DISEASES inferred ¹⁵
39	CDX2	Caudal Type Homeobox 2	Protein Coding	6.07	DISEASES inferred ¹⁵
40	ACTB	Actin Beta	Protein Coding	6.02	DISEASES inferred ¹⁵
41	RNF43	Ring Finger Protein 43	Protein Coding	6.02	DISEASES inferred ¹⁵
42	PGR	Progesterone Receptor	Protein Coding	5.95	DISEASES inferred ¹⁵
43	SMAD4	SMAD Family Member 4	Protein Coding	5.88	DISEASES inferred ¹⁵
44	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	5.86	DISEASES inferred ¹⁵

Sources

Variations for Ovary Adenocarcinoma

ClinVar genetic disease variations for Ovary Adenocarcinoma:

⁶

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	ERBB2	NM_004448.3(ERBB2):c.2570A>G (p.Asn857Ser)	SNV	Likely pathogenic	13880	rs28933370	GRCh37: 17:37881378-37881378 GRCh38: 17:39725125-39725125

Copy number variations for Ovary Adenocarcinoma from CNVD:

⁷

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	118124	17	7571720	7590868	Mutation	TP53	Ovarian adenocarcinomas

Sources

Expression for Ovary Adenocarcinoma

Search GEO for disease gene expression data for Ovary Adenocarcinoma.

Sources

Pathways for Ovary Adenocarcinoma

Pathways related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 77)

#	Super pathways	Score	Top Affiliating Genes
1	TGF-Beta Pathway ⁶³ Show member pathways JAK-STAT Pathway ⁶³ JNK Pathway ⁶³ MAPK Family Pathway ⁶³ Regulation of eIF4 and p70S6K ⁶³ SOCS Pathway ⁶³	13.59	TP53 PIK3CA KRAS HRAS ERBB2 BRCA1
2	Toll-like Receptor Signaling Pathway ³⁶ ¹ Show member pathways Chagas disease ³⁶ Hepatitis B ³⁶ Hepatitis C ³⁶ Lipid and atherosclerosis ³⁶ Regulation of toll-like receptor signaling pathway ¹	13.25	TP53 PIK3CA KRAS HRAS CTNNB1 BRAF
3	PI3K-Akt signaling pathway ³⁶ Show member pathways Human papillomavirus infection ³⁶	13.04	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
4	Human cytomegalovirus infection ³⁶ Show member pathways Human immunodeficiency virus 1 infection ³⁶ Kaposi sarcoma-associated herpesvirus infection ³⁶	12.99	TP53 PIK3CA KRAS HRAS CTNNB1 BAX
5	Focal Adhesion ³⁶ ¹ Show member pathways HGF Pathway ⁶³ Integrin-mediated Cell Adhesion ¹	12.96	PIK3CA KRAS HRAS ERBB2 CTNNB1 BRAF
6	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.91	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
7	Pathways in cancer ³⁶	12.86	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
8	MAPK signaling pathway ³⁶ ¹	12.81	TP53 KRAS HRAS ERBB2 BRAF
9	Ras signaling pathway ³⁶ Show member pathways Rap1 signaling pathway ³⁶	12.79	PIK3CA KRAS HRAS CTNNB1 BRAF
10	Downstream signaling events of B Cell Receptor (BCR) ⁶⁵ Show member pathways Activation of RAS in B cells ⁶⁵ Signaling by the B Cell Receptor (BCR) ⁶⁵	12.78	TP53 PIK3CA KRAS HRAS ERBB2
11	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁶ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁴	12.76	TP53 PIK3CA KRAS HRAS BAX
12	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.68	TP53 PIK3CA KRAS HRAS ERBB2 BRAF
13	Immune response IL-23 signaling pathway ²³ Show member pathways Angiopoietin receptor Tie2-mediated signaling ¹ Angiopoietin-TIE2 Signaling ⁶³ Development Angiopoietin - Tie2 signaling ²³ Development PDGF signaling via STATs and NF-kB ²³ IL23-mediated signaling events ¹ Immune response IL-10 signaling pathway ²³ Rac1/Pak1/p38/MMP-2 pathway ¹	12.64	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
14	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁵ MET activates STAT3 ⁶⁵ Neurotrophin signaling pathway ³⁶ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.64	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
15	mTOR signaling pathway (KEGG) ³⁶ Show member pathways mTOR Signaling Pathway ⁶⁴	12.58	TP53 PIK3CA KRAS HRAS ERBB2 BRAF
16	VEGF Signaling ⁶⁶ Show member pathways EGFR Signaling Pathway ⁶⁶ TGF-beta Signaling Pathway ⁶⁶ VEGF Signaling Pathway ⁶⁰	12.57	TP53 PIK3CA KRAS HRAS CTNNB1
17	Glioma ³⁶ Show member pathways Endocrine resistance ³⁶ Melanoma ³⁶ Non-small cell lung cancer ³⁶ Signaling Pathways in Glioblastoma ¹	12.57	TP53 PIK3CA KRAS HRAS ERBB2 BRCA1
18	Prolactin Signaling Pathway ¹ ³⁶ Show member pathways Development Prolactin receptor signaling ²³ Leptin signaling pathway ¹	12.54	PIK3CA KRAS HRAS ERBB2 BAX
19	Development VEGF signaling via VEGFR2 - generic cascades ²³ Show member pathways Development VEGF signaling and activation ²³ VEGF - VEGF R2 Signaling Pathways ⁶⁴	12.48	PIK3CA KRAS HRAS CTNNB1 BRCA1 BRAF
20	B cell receptor signaling pathway (KEGG) ³⁶ Show member pathways B Cell Receptor Signaling Pathway ¹ BCR signaling pathway ¹	12.45	PIK3CA KRAS HRAS BRAF
21	G-protein signaling RAC1 in cellular process ²³ Show member pathways CDC42 signaling events ¹ Cytoskeleton remodeling CDC42 in cellular processes ²³ RAC1 signaling pathway ¹	12.45	PIK3CA KRAS HRAS ERBB2 CTNNB1 BRAF
22	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.44	TP53 PIK3CA HRAS BAX
23	DNA Damage Response ¹ Show member pathways miRNA Regulation of DNA Damage Response ¹ p53 signaling pathway ³⁶	12.42	TP53 MIR17 BRCA1 BAX
24	Human T-cell leukemia virus 1 infection ³⁶	12.41	TP53 PIK3CA KRAS HRAS BAX
25	Translation Non-genomic (rapid) action of Androgen Receptor ²³ Show member pathways Basal cell carcinoma ³⁶ Transcription Androgen Receptor nuclear signaling ²³	12.4	TP53 PIK3CA HRAS ERBB2 CTNNB1 BAX
26	Apoptosis Pathway ⁶⁹ Show member pathways Akt Pathway ⁶⁹ NF-kappaB Pathway ⁶⁹	12.4	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
27	Viral carcinogenesis ³⁶	12.37	TP53 PIK3CA KRAS HRAS BAX
28	G-protein signaling Ras family GTPases in kinase cascades (scheme) ²³ Show member pathways Activation of the AP-1 family of transcription factors ⁶⁵ Immune response Oncostatin M signaling via MAPK in human cells ²³ MAPK Cascade ¹ Nanoparticle-mediated activation of receptor signaling ¹ Oncostatin M Signaling Pathway ¹	12.35	TP53 KRAS HRAS BRAF
29	MicroRNAs in cancer ³⁶	12.35	TP53 PIK3CA MIR30A MIR17 KRAS HRAS
30	Signaling by ERBB2 ⁶⁵ Show member pathways Downregulation of ERBB2 signaling ⁶⁵ Downregulation of ERBB2-ERBB3 signaling ⁶⁵ ERBB2 Activates PTK6 Signaling ⁶⁵ ERBB2 Regulates Cell Motility ⁶⁵ GRB2 events in ERBB2 signaling ⁶⁵ PI3K events in ERBB2 signaling ⁶⁵ PI3K events in ERBB4 signaling ⁶⁵ SHC1 events in ERBB2 signaling ⁶⁵ SHC1 events in ERBB4 signaling ⁶⁵	12.34	PIK3CA KRAS HRAS ERBB2
31	Development ERBB-family signaling ²³ Show member pathways Development EGFR signaling pathway ²³ EGF Pathway ⁶³ ErbB receptor signaling network ¹ GRB7 events in ERBB2 signaling ⁶⁵ PLCG1 events in ERBB2 signaling ⁶⁵	12.34	PIK3CA KRAS HRAS ERBB2 CTNNB1 BRAF
32	Signaling by FGFR2 ⁶⁵ Show member pathways FGFR2 ligand binding and activation ⁶⁵ FGFR2b ligand binding and activation ⁶⁵ Signaling by FGFR ⁶⁵	12.32	PIK3CA KRAS HRAS BRAF
33	Cell surface interactions at the vascular wall ⁶⁵ Show member pathways Fibronectin matrix formation ⁶⁵ PECAM1 interactions ⁶⁵ Tie2 Signaling ⁶⁵	12.28	PIK3CA KRAS HRAS CEACAM5
34	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁴ Show member pathways Akt Signaling Pathway ⁶⁴	12.28	TP53 PIK3CA KRAS HRAS ERBB2 BRAF
35	Colorectal Cancer Metastasis ⁶³	12.27	TP53 KRAS CTNNB1 BRAF BAX
36	mTOR Pathway ⁶⁹ Show member pathways Insulin Pathway ⁶⁹ TGF-beta Pathway ⁶⁹	12.26	TP53 PIK3CA KRAS HRAS BRAF
37	EGF/EGFR Signaling Pathway ¹	12.24	KRAS HRAS ERBB2 BRAF
38	NGF Pathway ⁶³ Show member pathways TRKA Signaling ⁶³	12.23	TP53 KRAS HRAS BRAF BAX
39	Longevity regulating pathway ³⁶ Show member pathways Longevity regulating pathway - multiple species ³⁶	12.22	TP53 PIK3CA KRAS HRAS BAX
40	Cellular senescence (KEGG) ³⁶	12.21	TP53 PIK3CA KRAS HRAS
41	Development EGFR signaling via small GTPases ²³ Show member pathways Development EGFR signaling via PIP3 ²³ Development PDGF signaling via MAPK cascades ²³ PDGF Pathway ¹	12.19	PIK3CA KRAS HRAS ERBB2
42	Signaling pathways regulating pluripotency of stem cells ³⁶	12.19	PIK3CA KRAS INHBA HRAS CTNNB1
43	Proteoglycans in cancer ³⁶	12.18	TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
44	FoxO signaling pathway ³⁶ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	12.14	PIK3CA KRAS HRAS BRAF
45	Integrated Breast Cancer Pathway ¹	12.12	TP53 KRAS CTNNB1 BRCA1 BRAF BAX
46	Thyroid hormone signaling pathway ³⁶	12.11	TP53 PIK3CA KRAS HRAS CTNNB1
47	Sphingolipid signaling pathway ³⁶	12.1	TP53 PIK3CA KRAS HRAS BAX
48	MAPK Pathway ⁶⁹ Show member pathways Toll-like Receptor Pathway ⁶⁹	12.09	TP53 PIK3CA ERBB2 BRAF
49	Development A2A receptor signaling ²³ Show member pathways Development A2B receptor- action via G-protein alpha s ²³	12.09	PIK3CA HRAS CTNNB1 BRAF
50	Glioblastoma Multiforme ⁶³	12.05	TP53 KRAS HRAS CTNNB1 BRAF

Sources

GO Terms for Ovary Adenocarcinoma

Biological processes related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell proliferation	GO:0008285	9.89	TP53 INHBA HRAS CTNNB1 BAX
2	regulation of cell proliferation	GO:0042127	9.78	TP53 CTNNB1 BRCA1 BRAF
3	nervous system development	GO:0007399	9.73	INHBA ESS2 ERBB2 CTNNB1 BAX ARID1A
4	Ras protein signal transduction	GO:0007265	9.69	TP53 KRAS HRAS
5	positive regulation of MAP kinase activity	GO:0043406	9.61	KRAS HRAS ERBB2
6	positive regulation of neuron apoptotic process	GO:0043525	9.58	TP53 CTNNB1 BAX
7	response to salt stress	GO:0009651	9.52	TP53 BAX
8	response to isolation stress	GO:0035900	9.46	KRAS HRAS
9	regulation of mitochondrial membrane permeability involved in apoptotic process	GO:1902108	9.37	TP53 BAX
10	negative regulation of neuron apoptotic process	GO:0043524	9.35	PIK3CA KRAS HRAS BRAF BAX
11	intrinsic apoptotic signaling pathway	GO:0097193	9.33	TP53 HRAS BAX
12	cellular response to indole-3-methanol	GO:0071681	9.32	CTNNB1 BRCA1
13	positive regulation of gene expression	GO:0010628	9.23	TP53 KRAS INHBA HRAS ERBB2 CTNNB1

Molecular functions related to Ovary Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	9.23	TP53 KRAS INHBA ERBB2 CEACAM5 BRCA1

Sources

Sources for Ovary Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Apr-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ Tocris

⁷⁰ UMLS

⁷¹ UMLS via Orphanet

⁷² UniProtKB/Swiss-Prot

⁷³ Wikipedia